Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) is a clinical-stage biotechnology company developing treatments for immune-mediated inflammatory diseases, with a focus on therapies that inhibit interleukin-1 beta (IL-1β). Its lead candidate, abdakibart, is a humanized monoclonal antibody designed to neutralize IL-1β and is… From the company’s description.
In fiscal 2025, Avalo Therapeutics, Inc. reported revenue of $0.06M, down 86.6% from fiscal 2024, and a net loss of $78.26M. Operations used $51.46M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Avalo Therapeutics, Inc. does
In the company’s own words
Avalo Therapeutics, Inc. (Nasdaq: AVTX) is a clinical-stage biotechnology company developing treatments for immune-mediated inflammatory diseases, with a focus on therapies that inhibit interleukin-1 beta (IL-1β). Its lead candidate, abdakibart, is a humanized monoclonal antibody designed to neutralize IL-1β and is being evaluated in a Phase 2 trial for hidradenitis suppurativa, a chronic inflammatory skin disease. The trial enrolls approximately 250 adults with moderate to severe disease. Avalo also has legacy candidates targeting LIGHT, mTOR, and B and T lymphocyte attenuator pathways, as well as a preclinical candidate for a mitochondrial disorder; it is not currently pursuing clinical development of these programs and is exploring strategic alternatives. The company acquired rights to abdakibart through its 2024 acquisition of AlmataBio, including licenses from Eli Lilly and Leap Therapeutics, and is responsible for its development and commercialization. Avalo relies on contract manufacturers to supply its product candidates and has limited sales and marketing resources.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WAYNE, PA
- Fiscal year end
- December
- CIK
- 1534120
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Avalo Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Avalo Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Avalo Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Avalo Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Avalo Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”